{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:15:12Z","timestamp":1780568112862,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10067-026-07976-5","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T17:46:07Z","timestamp":1770399967000},"page":"2413-2420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Overlapping autoimmunity and demyelination syndromes associated with TNF inhibitor therapy"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9333-455X","authenticated-orcid":false,"given":"Rula","family":"Daood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad E.","family":"Naffaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Azrilin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helana","family":"Jeries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Putterman","family":"Chaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"12","key":"7976_CR1","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1038\/s41433-024-03108-y","volume":"38","author":"N Jeyakumar","year":"2024","unstructured":"Jeyakumar N, Lerch M, Dale RC, Ramanathan S (2024) MOG antibody-associated optic neuritis. Eye (Lond) 38(12):2289\u20132301. https:\/\/doi.org\/10.1038\/s41433-024-03108-y","journal-title":"Eye (Lond)"},{"issue":"1","key":"7976_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ncl.2023.06.009","volume":"42","author":"L Cacciaguerra","year":"2024","unstructured":"Cacciaguerra L, Flanagan EP (2024) Updates in NMOSD and MOGAD diagnosis and treatment: a tale of two central nervous system autoimmune inflammatory disorders. Neurol Clin 42(1):77\u2013114. https:\/\/doi.org\/10.1016\/j.ncl.2023.06.009","journal-title":"Neurol Clin"},{"key":"7976_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.885218","volume":"13","author":"E Sechi","year":"2022","unstructured":"Sechi E, Cacciaguerra L, Chen JJ, Mariotto S, Fadda G, Dinoto A, Lopez-Chiriboga AS, Pittock SJ, Flanagan EP (2022) Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol 13:885218","journal-title":"Front Neurol"},{"issue":"5","key":"7976_CR4","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.55563\/clinexprheumatol\/17vmqc","volume":"42","author":"C Cardelli","year":"2024","unstructured":"Cardelli C, Zucchi D, Elefante E, Signorini V, Menchini M, Stagnaro C, Mosca M, Tani C (2024) Environment and systemic lupus erythematosus. Clin Exp Rheumatol 42(5):1104\u20131114. https:\/\/doi.org\/10.55563\/clinexprheumatol\/17vmqc","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"7976_CR5","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/rheumatology\/keu214","volume":"53","author":"G Moulis","year":"2014","unstructured":"Moulis G et al (2014) Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case\/non-case study in a nationwide pharmacovigilance database. Rheumatology (Oxford) 53(10):1864\u20131871","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"7976_CR6","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.autrev.2018.03.016","volume":"17","author":"A Vaglio","year":"2018","unstructured":"Vaglio A, Grayson PC, Fenaroli P, Gianfreda D, Boccaletti V, Ghiggeri GM, Moroni G (2018) Drug-induced lupus: traditional and new concepts. Autoimmun Rev 17(9):912\u2013918. https:\/\/doi.org\/10.1016\/j.autrev.2018.03.016","journal-title":"Autoimmun Rev"},{"issue":"7","key":"7976_CR7","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.2215\/CJN.01910215","volume":"10","author":"JJ Hogan","year":"2015","unstructured":"Hogan JJ, Markowitz GS, Radhakrishnan J (2015) Drug-induced glomerular disease: immune-mediated injury. Clin J Am Soc Nephrol 10(7):1300\u20131310. https:\/\/doi.org\/10.2215\/CJN.01910215","journal-title":"Clin J Am Soc Nephrol"},{"key":"7976_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11010038","volume":"11","author":"LB Kristensen","year":"2021","unstructured":"Kristensen LB, Lambertsen KL, Nguyen N, Byg K-E, Nielsen HH (2021) The role of non-selective TNF inhibitors in demyelinating events. Brain Sci 11:38. https:\/\/doi.org\/10.3390\/brainsci11010038","journal-title":"Brain Sci"},{"key":"7976_CR9","doi-asserted-by":"crossref","unstructured":"(1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group. Neurology 53(3):457\u201365","DOI":"10.1212\/WNL.53.3.457"},{"issue":"12","key":"7976_CR10","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::aid-art474>3.0.co;2-w","volume":"44","author":"N Mohan","year":"2001","unstructured":"Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN (2001) Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44(12):2862\u20132869. https:\/\/doi.org\/10.1002\/1529-0131(200112)44:12%3c2862::aid-art474%3e3.0.co;2-w","journal-title":"Arthritis Rheum"},{"issue":"2","key":"7976_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ajo.2013.03.037","volume":"156","author":"E Eggenberger","year":"2013","unstructured":"Eggenberger E (2013) Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic therapy (SABER) study. Am J Ophthalmol 156(2):407\u2013408. https:\/\/doi.org\/10.1016\/j.ajo.2013.03.037","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"7976_CR12","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","volume":"16","author":"M P\u00e9rez-De-Lis","year":"2017","unstructured":"P\u00e9rez-De-Lis M, Retamozo S, Flores-Ch\u00e1vez A, Kostov B, Perez-Alvarez R, Brito-Zer\u00f3n P, Ramos-Casals M (2017) Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin Drug Saf 16(11):1255\u20131271. https:\/\/doi.org\/10.1080\/14740338.2017.1372421","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"7976_CR13","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","volume":"77","author":"A Kunchok","year":"2020","unstructured":"Kunchok A, Aksamit AJ Jr, Davis JM 3rd, Kantarci OH, Keegan BM, Pittock SJ, Weinshenker BG, McKeon A (2020) Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurol 77(8):937\u2013946. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1162","journal-title":"JAMA Neurol"},{"issue":"2","key":"7976_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5114\/reum.2021.105438","volume":"59","author":"EJ Kucharz","year":"2021","unstructured":"Kucharz EJ, Kotulska-Kucharz A (2021) Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it? Reumatologia 59(2):65\u201367. https:\/\/doi.org\/10.5114\/reum.2021.105438","journal-title":"Reumatologia"},{"issue":"4","key":"7976_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/20552173221128170","volume":"8","author":"N Molazadeh","year":"2022","unstructured":"Molazadeh N, Bose G, Lotan I, Levy M (2022) Autoimmune diseases and cancers overlapping with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a systematic review. Mult Scler J Exp Transl Clin 8(4):20552173221128170. https:\/\/doi.org\/10.1177\/20552173221128170","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"7976_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.msard.2018.12.006","volume":"28","author":"M Philippart","year":"2019","unstructured":"Philippart M, Fastr\u00e9 S, Rahier JF, London F (2019) First report of coexistence of MOG-antibody-positive disease and Crohn\u2019s disease. Mult Scler Relat Disord 28:1\u20133. https:\/\/doi.org\/10.1016\/j.msard.2018.12.006","journal-title":"Mult Scler Relat Disord"},{"key":"7976_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.msard.2018.08.029","volume":"26","author":"E Lommers","year":"2018","unstructured":"Lommers E, Depierreux F, Hansen I, Dive D, Maquet P (2018) NMOSD with anti-MOG antibodies following anti-TNF\u03b1 therapy: a case report. Mult Scler Relat Disord 26:37\u201339. https:\/\/doi.org\/10.1016\/j.msard.2018.08.029","journal-title":"Mult Scler Relat Disord"},{"key":"7976_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102889","volume":"51","author":"W Luo","year":"2021","unstructured":"Luo W, Li R, Chang Y, She H, Kermode AG, Qiu W (2021) Myelin oligodendrocyte glycoprotein antibody-associated disorders coexisting with ankylosing spondylitis: potential association between demyelination and tumor necrosis factor inhibitors. Mult Scler Relat Disord 51:102889. https:\/\/doi.org\/10.1016\/j.msard.2021.102889","journal-title":"Mult Scler Relat Disord"},{"key":"7976_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120044","volume":"432","author":"V Redenbaugh","year":"2022","unstructured":"Redenbaugh V, Flanagan EP, Floris V, Zara P, Bhatti MT, Sanchez F, Koster M, Mariotto S, Pittock SJ, Chen JJ, Cauli A, Solla P, Sechi E (2022) Exposure to TNF inhibitors is rare at MOGAD presentation. J Neurol Sci 432:120044. https:\/\/doi.org\/10.1016\/j.jns.2021.120044","journal-title":"J Neurol Sci"},{"issue":"6","key":"7976_CR20","doi-asserted-by":"publisher","DOI":"10.12890\/2025_005467","volume":"12","author":"S Baddam","year":"2025","unstructured":"Baddam S, Patel S, Kahlon N, Thiriveedi M (2025) Unmasking myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): CNS demyelination triggered by TNF inhibition in a patient with ankylosing spondylitis. Eur J Case Rep Intern Med 12(6):005467. https:\/\/doi.org\/10.12890\/2025_005467","journal-title":"Eur J Case Rep Intern Med"},{"issue":"3","key":"7976_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/ar4582","volume":"16","author":"E Kaltsonoudis","year":"2014","unstructured":"Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA (2014) Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res Ther 16(3):R125. https:\/\/doi.org\/10.1186\/ar4582","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"7976_CR22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.5606\/tftrd.2023.9489","volume":"69","author":"SM T\u00fcrk","year":"2022","unstructured":"T\u00fcrk SM, Kotan D, G\u00f6n\u00fcll\u00fc E, \u00d6zt\u00fcrk Z, Karata\u015f D (2022) Case of MOG-IgG-associated disease with ankylosing spondylitis: a rare coexistence. Turk J Phys Med Rehabil 69(4):545\u2013548. https:\/\/doi.org\/10.5606\/tftrd.2023.9489","journal-title":"Turk J Phys Med Rehabil"},{"issue":"3","key":"7976_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/0961203320978514","volume":"30","author":"L Caroline Breis","year":"2021","unstructured":"Caroline Breis L, Ant\u00f4nio Machado Schlindwein M, Pastor Bandeira I, Machiavelli Fontana T, Fiuza Parolin L, Weingrill P, Kleinpaul Vieira RG, Vin\u00edcius Magno Gon\u00e7alves M (2021) MOG-IgG-associated disorder and systemic lupus erythematosus disease: systematic review. Lupus 30(3):385\u2013392. https:\/\/doi.org\/10.1177\/0961203320978514","journal-title":"Lupus"},{"key":"7976_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/1352458517699791","volume":"24","author":"N Asgari","year":"2018","unstructured":"Asgari N, Jarius S, Laustrup H et al (2018) Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: a predominantly population-based study. Mult Scler J 24:331\u2013339","journal-title":"Mult Scler J"},{"key":"7976_CR25","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1177\/1352458515613165","volume":"22","author":"KT Kovacs","year":"2016","unstructured":"Kovacs KT, Kalluri SR, Boza-Serrano A et al (2016) Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: a preliminary study. Mult Scler 22:1192\u20131201","journal-title":"Mult Scler"},{"key":"7976_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jneuroim.2011.09.005","volume":"240\u2013241","author":"PH Lalive","year":"2011","unstructured":"Lalive PH, Molnarfi N, Benkhoucha M, Weber MS, Santiago-Raber ML (2011) Antibody response in MOG 35\u201355 induced EAE. J Neuroimmunol 240\u2013241:28\u201333. https:\/\/doi.org\/10.1016\/j.jneuroim.2011.09.005","journal-title":"J Neuroimmunol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-07976-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-07976-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-07976-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:21:28Z","timestamp":1773217288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-07976-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7976"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-07976-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"All authors provided consent for publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study was approved by the Helsinki Committees of the Galilee Medical Center; informed consent was waived due to the retrospective and anonymized nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}